Murine leukemia virus cDNA and Antigen

Murine Leukemia Virus (MLV) is a retrovirus that can cause cancer in mice. It has a genome composed of RNA and can convert itself into DNA, which it then integrates into the host genome. MLV encodes several proteins, including envelope proteins, a putative envelope polyprotein, and integrase.

The envelope protein is responsible for viral entry into host cells, while the putative envelope polyprotein may play a role in viral assembly and release. Integrase, on the other hand, is an enzyme that enables the integration of the viral DNA into the host genome.

MLV has been widely studied as a model for retroviral biology and has been used extensively in gene therapy research. Understanding the function of its various proteins can help inform the development of potential treatments for retroviral infections and related diseases.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E.coli expression Vector), which are ready for production of the recombinant proteins.